New study identifies SARS component as drug target
respiratory syndrome (SARS) virus that looks to be a promising
target for new anti-SARS virus drugs.
This bit of research becomes the latest work to finding an effective treatment and cure for SARS, a respiratory disease in humans that is caused by the SARS coronavirus.
There was one major epidemic to date, between November 2002 and July 2003, with 8,096 known cases of the disease, and 774 deaths (a mortality rate of 9.6 per cent) being listed in the WHO's April 21, 2004 concluding report.
Scientists at the US Department of Energy's Brookhaven National Laboratory have set the stage for the rapid identification of compounds to fight against SARS.
By studying the SARS main proteinase enzyme used by the virus during infection, they revealed that the proteinase is inactive when in the form of single molecules.
But once two of those molecules bind together the enzyme becomes active and is able to play its role in SARS virus reproduction.
The challenge for researchers, and the focus of the Brookhaven study, was to determine the concentration at which individual proteinase molecules form active dimers.
Knowing this concentration, for which estimates at other laboratories have varied greatly, would allow researchers to search for anti-SARS drugs more efficiently by ensuring that the proteinase used in tests is initially in its active form.
"Although vaccines against viruses are very effective, vaccines for viruses that mutate rapidly - such as the viruses that cause SARS, AIDS, and bird flu - are much more difficult to obtain," said Brookhaven biologist Walter Mangel, the lead author of the paper.
"Even if a vaccine is available, antiviral agents are important in stopping the spread of highly infectious viruses. If antiviral agents for SARS had been available, they could have been used to contain the outbreak to the initial site of the infection," he added.
Using three different scientific techniques, including x-ray scattering at the NSLS, the Brookhaven researchers obtained almost identical values for this concentration. Now that this crucial value has been narrowed down to a precise range, researchers can focus on finding compounds that bind to the active form of the enzyme.
"Targets for antiviral drugs must be carefully chosen such that binding to it prevents the virus from reproducing," Mangel said. "Viral proteinases are excellent targets for antiviral drugs. One reason so many people are surviving the AIDS epidemic is the effectiveness of drugs targeted to the proteinase of human immunodeficiency virus (HIV)."
One way to obtain compounds that bind to a proteinase is via high-throughput screening.
Chemical libraries containing tens of thousands of small compounds are available that can be searched for effective drugs against various diseases.
Small amounts of a target, e.g., an active viral proteinase, are placed in tiny wells in a plate, and a different compound from the library is added to each well.
To determine whether a compound binds to and inhibits the proteinase, an additional molecule is added that changes colour in the presence of an active proteinase.
Wells that don't show a color change therefore contain compounds that inhibit the proteinase, and could be effective antiviral agents.
Earlier this year, Mangel's research group published a procedure on the synthesis of a new compound that changes colour in the presence of the active form of the SARS main proteinase.
However, for this screening process to work, the SARS proteinase inserted into the wells has to be active to begin with. Knowing the concentration range for dimer formation will therefore help researchers in their search for a compound to stop the virus. "Now that the stage is set, high-throughput screening can begin," Mangel said.
"Hopefully, it will yield an antiviral agent that can be stockpiled before a virulent strain of the virus reappears."
Antibiotics currently used to treat SARS remain wholly ineffective and treatment of SARS so far has been largely supportive with antipyretics, supplemental oxygen and ventilatory support as needed.
Suspected cases of SARS must be isolated, preferably in negative pressure rooms, with full barrier nursing precautions taken for any necessary contact with these patients.
There was initially support for steroids and the antiviral drug ribavirin, but no published evidence has supported this therapy. Many clinicians now suspect that ribavirin is detrimental.
Results from the Brookhaven study were published online by Biochemistry on November 17, 2006.
